본문 바로가기
KERD
논문KCI 등재

From Gut to Brain: Alteration in Inflammation Markers in the Brain of Dextran Sodium Sulfate-induced Colitis Model Mice

0

조회

0

다운로드

4

인용

0

참고문헌

키워드

초록

Objective: Neuropsychiatric manifestations like depression and cognitive dysfunction commonly occur in inflammatory bowel disease (IBD). In the context of the brain-gut axis model, colitis can lead to alteration of brain function in a bottom-up manner. Here, the changes in the response of the hypothalamic-pituitary-adrenal axis and inflammationrelated markers in the brain in colitis were studied. Methods: Dextran sodium sulfate (DSS) was used to generate a mouse model of colitis. Mice were treated with DSS for 3 or 7 days and sacrificed. We analyzed the gene expression of brain-derived neurotrophic factor (BDNF), cyclooxygenase 2 (COX-2), and glial fibrillary acidic protein (GFAP), and the expression of GFAP, in the hippocampus, hypothalamus, and amygdala. Additionally, the levels of C-reactive protein (CRP) and serum cortisol/corticosterone were measured. Results: Alteration of inflammatory-related markers varied depending on the brain region and exposure time. In the hippocampus, COX-2 mRNA, GFAP mRNA, and GFAP expression were upregulated during exposure to DSS. However, in the hypothalamus, COX-2 mRNA was upregulated only 3 days after treatment. In the amygdala, BDNF and COX-2 mRNAs were downregulated. CRP and corticosterone expression increased with DSS treatment at day 7. Conclusion: IBD could lead to neuroinflammation in a bottom-up manner, and this effect varied according to brain region. Stress-related hormones and serum inflammatory markers, such as CRP, were upregulated from the third day of DSS treatment. Therefore, early and active intervention is required to prevent psychological and behavioral changes caused by IBD, and region-specific studies can help understand the precise mechanisms by which IBD affects the brain

Abstract

Objective: Neuropsychiatric manifestations like depression and cognitive dysfunction commonly occur in inflammatory bowel disease (IBD). In the context of the brain-gut axis model, colitis can lead to alteration of brain function in a bottom-up manner. Here, the changes in the response of the hypothalamic-pituitary-adrenal axis and inflammationrelated markers in the brain in colitis were studied. Methods: Dextran sodium sulfate (DSS) was used to generate a mouse model of colitis. Mice were treated with DSS for 3 or 7 days and sacrificed. We analyzed the gene expression of brain-derived neurotrophic factor (BDNF), cyclooxygenase 2 (COX-2), and glial fibrillary acidic protein (GFAP), and the expression of GFAP, in the hippocampus, hypothalamus, and amygdala. Additionally, the levels of C-reactive protein (CRP) and serum cortisol/corticosterone were measured. Results: Alteration of inflammatory-related markers varied depending on the brain region and exposure time. In the hippocampus, COX-2 mRNA, GFAP mRNA, and GFAP expression were upregulated during exposure to DSS. However, in the hypothalamus, COX-2 mRNA was upregulated only 3 days after treatment. In the amygdala, BDNF and COX-2 mRNAs were downregulated. CRP and corticosterone expression increased with DSS treatment at day 7. Conclusion: IBD could lead to neuroinflammation in a bottom-up manner, and this effect varied according to brain region. Stress-related hormones and serum inflammatory markers, such as CRP, were upregulated from the third day of DSS treatment. Therefore, early and active intervention is required to prevent psychological and behavioral changes caused by IBD, and region-specific studies can help understand the precise mechanisms by which IBD affects the brain

참고문헌 (55)

  1. Bernstein CN, "World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010", Inflamm Bowel Dis, 16, pp.112~124 (2010)
  2. Loftus EV Jr, "Clinical epidemiology of inflammatory bowel disease:Incidence, prevalence, and environmental influences", Gastroenterology, 126, pp.1504~1517 (2004)
  3. Irvine EJ, "Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group", Gastroenterology, 106, pp.287~296 (1994)
  4. Husain A, "Communicating with patients with inflammatory bowel disease", Inflamm Bowel Dis, 10, pp.444~450 (2004)
  5. Karwowski CA, "Strategies to improve quality of life in adolescents with inflammatory bowel disease", Inflamm Bowel Dis, 15, pp.1755~1764 (2009)
  6. Bernstein CN, "The prevalence of extraintestinal diseases in inflammatory bowel disease:a population-based study", Am J Gastroenterol, 96, pp.1116~1122 (2001)
  7. Zois CD, "Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights", J Crohns Colitis, 4, pp.115~124 (2010)
  8. Levine JS, "Extraintestinal manifestations of inflammatory bowel disease", Gastroenterol Hepatol, 7, pp.235~241 (2011)
  9. Mikocka-Walus A, "Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases", Inflamm Bowel Dis, 22, pp.752~762 (2016)
  10. Alper Evrensel, "Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders", Clinical Psychopharmacology and Neuroscience, 14(3), pp.231~237 (2016), 대한정신약물학회
  11. Foster JA, "Gut-brain axis: how the microbiome influences anxiety and depression", Trends Neurosci, 36, pp.305~312 (2013)
  12. Stilling RM, "Microbial genes, brain & behaviour - epigenetic regulation of the gut-brain axis", Genes Brain Behav, 13, pp.69~86 (2014)
  13. Alan C. Logan, "The Microbiome and Mental Health: Looking Back, Moving Forward with Lessons from Allergic Diseases", Clinical Psychopharmacology and Neuroscience, 14(2), pp.131~147 (2016), 대한정신약물학회
  14. Ghaisas S, "Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases", Pharmacol Ther, 158, pp.52~62 (2016)
  15. McEwen BS, "Re-examination of the glucocorticoid hypothesis of stress and aging", Prog Brain Res, 93, pp.365~381 (1992)
  16. Reagan LP, "Controversies surrounding glucocorticoid-mediated cell death in the hippocampus", J Chem Neuroanat, 13, pp.149~167 (1997)
  17. Gould E, "Learning enhances adult neurogenesis in the hippocampal formation", Nat Neurosci, 2, pp.260~265 (1999)
  18. Sapolsky RM, "Glucocorticoids, stress, and their adverse neurological effects: relevance to aging", Exp Gerontol, 34, pp.721~732 (1999)
  19. Conrad CD, "Chronic stress-induced hippocampal vulnerability:the glucocorticoid vulnerability hypothesis", Rev Neurosci, 19, pp.395~411 (2008)
  20. Reber SO, "Stress and animal models of inflammatory bowel disease--an update on the role of the hypothalamo-pituitary-adrenal axis", Psychoneuroendocrinology, 37, pp.1~19 (2012)
  21. Reichmann F, "Dextran sulfate sodium-induced colitis alters stress-associated behaviour and neuropeptide gene expression in the amygdala-hippocampus network of mice", Sci Rep, 5, pp.9970~ (2015)
  22. Bettio LE, "Guanosine prevents behavioral alterations in the forced swimming test and hippocampal oxidative damage induced by acute restraint stress", Pharmacol Biochem Behav, 127, pp.7~14 (2014)
  23. Mifsud KR, "Rapid down-regulation of glucocorticoid receptor gene expression in the dentate gyrus after acute stress in vivo:role of DNA methylation and microRNA activity", Neuroendocrinology, 104, pp.157~169 (2017)
  24. Bonaz BL, "Brain-gut interactions in inflammatory bowel disease", Gastroenterology, 144, pp.36~49 (2013)
  25. Martin-Subero M, "Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gutbrain pathways", CNS Spectr, 21, pp.184~198 (2016)
  26. Ruifrok AC, "Quantification of histochemical staining by color deconvolution", Anal Quant Cytol Histol, 23, pp.291~299 (2001)
  27. Zonis S, "Chronic intestinal inflammation alters hippocampal neurogenesis", J Neuroinflammation, 12, pp.65~ (2015)
  28. Font-Nieves M, "Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes", J Biol Chem, 287, pp.6454~6468 (2012)
  29. Sil S, "Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer’s disease", J Neuroimmunol, 291, pp.115~124 (2016)
  30. Bignami A, "Astrocyte-specific protein and neuroglial differentiation. An immunofluorescence study with antibodies to the glial fibrillary acidic protein", J Comp Neurol, 153, pp.27~38 (1974)
  31. O’Callaghan JP, "Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity", Expert Opin Drug Saf, 4, pp.433~442 (2005)
  32. Yang Z, "Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker", Trends Neurosci, 38, pp.364~374 (2015)
  33. Eng LF, "Astrocytic response to injury", Prog Brain Res, 94, pp.353~365 (1992)
  34. Eng LF, "GFAP and astrogliosis", Brain Pathol, 4, pp.229~237 (1994)
  35. Nagele RG, "Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease", Neurobiol Aging, 25, pp.663~674 (2004)
  36. Jacobsen JP, "Chronic corticosterone decreases brainderived neurotrophic factor (BDNF) mRNA and protein in the hippocampus, but not in the frontal cortex, of the rat", Brain Res, 1110, pp.221~225 (2006)
  37. Schaaf MJ, "Corticosterone effects on BDNF expression in the hippocampus. Implications for memory formation", Stress, 3, pp.201~208 (2000)
  38. O’Banion MK, "Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology", Crit Rev Neurobiol, 13, pp.45~82 (1999)
  39. Schaaf MJ, "Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone", Brain Res, 813, pp.112~120 (1998)
  40. Yamagata K, "Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids", Neuron, 11, pp.371~386 (1993)
  41. O’Callaghan JP, "Glucocorticoids regulate the concentration of glial fibrillary acidic protein throughout the brain", Brain Res, 494, pp.159~161 (1989)
  42. Lindsay RM, "Placode and neural crest-derived sensory neurons are responsive at early developmental stages to brain-derived neurotrophic factor", Dev Biol, 112, pp.319~328 (1985)
  43. Hofer MM, "Brain-derived neurotrophic factor prevents neuronal death in vivo", Nature, 331, pp.261~262 (1988)
  44. Sannino G, "Acute stress enhances the expression of neuroprotection- and neurogenesis-associated genes in the hippocampus of a mouse restraint model", Oncotarget, 7, pp.8455~8465 (2016)
  45. Gray JD, "Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors", Neuroscience, 239, pp.214~227 (2013)
  46. Duman RS, "A molecular and cellular theory of depression", Arch Gen Psychiatry, 54, pp.597~606 (1997)
  47. Suliman S, "Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: sys tematic review and meta-regression analysis", Front Integr Neurosci, 7, pp.55~ (2013)
  48. Guilloux JP, "Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression", Mol Psychiatry, 17, pp.1130~1142 (2012)
  49. Hamilton JP, "Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies", Mol Psychiatry, 13, pp.993~1000 (2008)
  50. Kimbrell TA, "Regional cerebral glucose utilization in patients with a range of severities of unipolar depression", Biol Psychiatry, 51, pp.237~252 (2002)
  51. Agostini A, "Brain functional changes in patients with ulcerative colitis: a functional magnetic resonance imaging study on emotional processing", Inflamm Bowel Dis, 17, pp.1769~1777 (2011)
  52. Breder CD, "Characterization of inducible cyclooxygenase in rat brain", J Comp Neurol, 355, pp.296~315 (1995)
  53. Chen C, "Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity", J Neurophysiol, 87 (2002)
  54. Albrecht D, "Angiotensin-(1-7)-induced plasticity changes in the lateral amygdala are mediated by COX-2 and NO", Learn Mem, 14, pp.177~184 (2007)
  55. Noh H, "Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain", Neurochem Int, 69, pp.35~40 (2014)

관련 논문AI추천

Inflammatory Bowel Disease and Neurodegenerative DiseasesChen Mu-Hong, Kim Jin Sun, Lu Ching-Liang, Wang Hohui E., Wang Yen-Po, Zhang Bing거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제4호Neuroinflammation, Gut-Brain Axis and DepressionAlper Evrensel, Barıs¸ Önen Ünsalver, Mehmet Emin Ceylan대한신경정신의학회 · PSYCHIATRY INVESTIGATION2020 · 제17권 제1호Depression Promotes the Onset of Irritable Bowel Syndrome through Unique Dysbiosis in RatsAkinori Wada, Chie Kurihara, Chikako Watanabe, Hanae Tsuchihashi, Hirotaka Furuhashi, Hiroyuki Toda, Katsunori Kimura, Kazuhiko Shirakabe, Kazuki Horiuchi, Kengo Tomita, Kenichi Inaba, Kunio Shimizu, Masaaki Higashiyama, Masaaki Tanichi, Naoki Shibuya, Nao Sugihara, Ryota Hokari, Shigeaki Nagao, Shingo Enomoto, Shunsuke Komoto, Soichiro Miura, Takeshi Takajo, Yoshikiyo Okada, Yoshinori Hanawa거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제3호Inflammation as the Potential Basis in Depression맹성호, 홍희옥대한배뇨장애요실금학회 · International Neurourology Journal2019 · 제23권 제4호Effects of Treadmill Exercise on Stress-Induced Gut Microbiota Dysbiosis and Brain Dysfunction박상서, 신말순한국운동재활복지협회 · 운동재활·복지2025 · 제6권 제2호The Gut-Brain Axis: The Missing Link in DepressionAlper Evrensel, Mehmet Emin Ceylan대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제3호

이 간행물의 다른 논문 (17건)